Login to Your Account

Other News To Note

Tuesday, October 25, 2011
PolyMedix Inc., of Radnor, Pa., presented clinical and preclinical data that showed its defensin-mimetic antibiotic, PMX-30063, may be active against Gram-positive and certain evaluated Gram-negative organisms, including multidrug-resistant species. In a Phase I trial, PMX-30063 also demonstrated antimicrobial activity in human blood plasma against both resistant and susceptible strains of Staphylococcus aureus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription